DK2442814T3 - Bifidobakterier til behandling af diabetes og relaterede tilstande - Google Patents

Bifidobakterier til behandling af diabetes og relaterede tilstande Download PDF

Info

Publication number
DK2442814T3
DK2442814T3 DK10730548.4T DK10730548T DK2442814T3 DK 2442814 T3 DK2442814 T3 DK 2442814T3 DK 10730548 T DK10730548 T DK 10730548T DK 2442814 T3 DK2442814 T3 DK 2442814T3
Authority
DK
Denmark
Prior art keywords
combination
bifidobacterium
use according
ncfm
insulin
Prior art date
Application number
DK10730548.4T
Other languages
English (en)
Inventor
Rémy Burcelin
Didier Carcano
Sampo Lahtinen
Original Assignee
Dupont Nutrition Biosci Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Nutrition Biosci Aps filed Critical Dupont Nutrition Biosci Aps
Application granted granted Critical
Publication of DK2442814T3 publication Critical patent/DK2442814T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (16)

1. Kombination af: (i) en bakterie fra slægten Bifidobacterium eller en blanding deraf; og (ii) et antidiabetikum valgt blandt et biguanid eller en dipeptidylpeptidase-4 (DPP-4)-inhibitor; til anvendelse til behandling af en eller flere af følgende sygdomme og tilstande (a) til (g) hos et pattedyr: (a) behandling af diabetes; (b) behandling af metabolisk syndrom; (c) behandling af nedsat glucosetolerans; (d) normalisering af insulinfølsomhed; (e) forøgelse af insulinsekretion i ikke-fastende tilstand; (f) reducering af insulinsekretion i fastende tilstand; (g) behandling af obesitas, kontrol af vægtstigning, inducering af vægttab, reducering af kropsfedtmassen og/eller reducering af mesenterisk fedtmasse.
2. Kombination til anvendelse ifølge krav 1, hvor diabetes er type 2-diabetes.
3. Kombination til anvendelse ifølge krav 1 eller krav 2, hvor pattedyret, der har behov for behandlingen, indtaget en kost med højt fedtindhold.
4. Kombination til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor bifidobakterien er en probiotisk bifidobakterie eller en blanding deraf.
5. Kombination til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor bifidobakterien er valgt blandt arterne Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis og Bifidobacterium angulatum og blandinger af hvilke som helst deraf .
6. Kombination til anvendelse ifølge krav 5, hvor bifidobakterien er af arten Bifidobacterium animalis.
7. Kombination til anvendelse ifølge krav 6, hvor bifidobakterien er af arten Bifidobacterium animalis subsp. lactis.
8. Kombination til anvendelse ifølge krav 6 eller krav 7, hvor bifidobakterien er Bifidobacterium animalis subsp. lactis stamme 420 (B420).
9. Kombination til anvendelse ifølge et hvilket som helst af kravene 1 til 4, der yderligere indbefatter en bakterie af slægten Lactobacillus eller en blanding deraf.
10. Kombination til anvendelse ifølge krav 9, hvor den yderligere bakterie er af arten Lactobacillus acidophilus.
11. Kombination til anvendelse ifølge krav 10, hvor bakterien er Lactobacillus acidophilus stamme NCFM (ATCC PTA-4797).
12. Kombination til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor antidiabetikummet er valgt blandt metformin, alogliptin, saxagliptin, sitagliptin eller vildagliptin.
13. Kombination til anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor antidiabetikummet er metformin.
14. Kombination til anvendelse ifølge et hvilket som helst af kravene 1 til 13, der yderligere indeholder et præbiotikum.
15. Kombination til anvendelse ifølge krav 14, hvor præbiotikummet er valgt blandt alginat, xanthan, pectin, johannesbrødgummi, inulin, guargummi, et galactooligosaccharid, et fructooligosaccharid, polydextrose, lactitol, lactosaccharose, et sojabønneoligosaccharid, isomaltulose, et isomaltooligosaccharid, et glucooligosaccharid, et xylooligosaccharid, et mannooligosaccharid, en beta-glucan, cellobiose, raffinose, gentiobiose, melibiose, xylobiose, et cyclodextrin, isomaltose, trehalose, stachyose, panose, pullulan, verbascose, en galactomannan eller en resistent stivelse.
16. Kombination til anvendelse ifølge krav 15, hvor præbiotikummet er polydextrose.
DK10730548.4T 2009-06-19 2010-06-18 Bifidobakterier til behandling af diabetes og relaterede tilstande DK2442814T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21856309P 2009-06-19 2009-06-19
PCT/IB2010/052757 WO2010146568A2 (en) 2009-06-19 2010-06-18 Bifidobacteria for treating diabetes and related conditions

Publications (1)

Publication Number Publication Date
DK2442814T3 true DK2442814T3 (da) 2019-01-14

Family

ID=42989263

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17155654.1T DK3181134T3 (da) 2009-06-19 2010-06-18 Bifidobakterier til behandling af diabetes og relaterede tilstande
DK10730548.4T DK2442814T3 (da) 2009-06-19 2010-06-18 Bifidobakterier til behandling af diabetes og relaterede tilstande
DK14179491.7T DK2808024T3 (da) 2009-06-19 2010-06-18 Bifidobakterier til behandling af kongestiv hjerteinsufficiens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17155654.1T DK3181134T3 (da) 2009-06-19 2010-06-18 Bifidobakterier til behandling af diabetes og relaterede tilstande

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14179491.7T DK2808024T3 (da) 2009-06-19 2010-06-18 Bifidobakterier til behandling af kongestiv hjerteinsufficiens

Country Status (7)

Country Link
US (8) US20120107291A1 (da)
EP (3) EP2442814B1 (da)
CN (5) CN104784220A (da)
DK (3) DK3181134T3 (da)
ES (3) ES2763137T3 (da)
PL (3) PL2442814T3 (da)
WO (1) WO2010146568A2 (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670661B (zh) * 2011-03-08 2013-10-02 惠宏襄 用于刺激胰高血糖素样肽-1分泌的药物
ITMI20111488A1 (it) 2011-08-03 2013-02-04 Gnosis Spa Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita'
CN103082292B (zh) * 2011-11-02 2015-03-04 深圳华大基因研究院 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
CN102792919B (zh) 2012-08-08 2015-09-09 上海交通大学 悉生动物肥胖模型的构建方法及其应用
DK2895012T3 (da) * 2012-09-11 2018-01-22 Thylabisco Ab Præbiotisk thylakoid-sammensætning
CA2885537C (en) * 2012-09-20 2021-11-23 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
EP2935560A4 (en) * 2012-12-20 2016-08-31 Gervais Danone Sa USE OF BIFIDOBACTERIUM ANIMALIS TO TREAT OR PREVENT BODY WEAKNESS INCREASE AND INSULIN RESISTANCE
ES2526986B1 (es) 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
CA2926466C (en) * 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof
US10058576B2 (en) 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
RU2673341C2 (ru) * 2014-02-14 2018-11-26 Везаль Фарма Са Применение композиций, содержащих bifidobacterium animalis ssp. lactis lmg p-28149
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
BE1000016B1 (fr) * 2014-04-25 2016-02-01 Vesale Pharma Nv Composition comprenant du bifidobacterium animalis ssp. lactis.
WO2015121455A1 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant au moins un probiotique
BE1000017B1 (fr) * 2014-04-25 2016-01-21 Vesale Pharma Nv Composition comprenant au moins un probiotique
WO2016020485A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. A combination of vitamin d and zinc and its use
WO2016020486A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. A combination of myo-inositol and zinc and its use
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
TWI572713B (zh) * 2014-10-31 2017-03-01 豐華生物科技股份有限公司 抗肥胖之乳酸菌菌株及其於食品組成物以及醫藥組成物之應用
US10231941B2 (en) 2015-01-23 2019-03-19 Temple University—Of The Commonwealth System of Higher Educaton Use of short chain fatty acids in cancer prevention
GB201514303D0 (en) * 2015-07-16 2015-09-23 Dupont Nutrition Biosci Aps Bifidobacteria for treating cardiac conditions
GB201514302D0 (en) * 2015-07-16 2015-09-23 Dupont Nutrition Biosci Aps Lactobacilli for treating cardiac dysfunction
US9980491B2 (en) * 2015-07-25 2018-05-29 Siobhan Reilly Probiotic compositions and methods of use
EP3173085A1 (en) * 2015-11-30 2017-05-31 Vaiomer Polydextrose for the prevention and/or treatment of heart failure
CN105770892A (zh) * 2016-02-04 2016-07-20 烟台金海药业有限公司 一种防治鸡心包积液-肝炎综合征生物兽药的制备方法
CN105797156A (zh) * 2016-03-15 2016-07-27 烟台金海药业有限公司 一种防治hhs的抗原抗体复合物制剂的制备方法
CN107224584A (zh) * 2016-03-25 2017-10-03 上海来益生物药物研究开发中心有限责任公司 一种益生菌组合物及其应用
KR20220001516A (ko) * 2016-04-14 2022-01-05 듀폰 뉴트리션 바이오사이언시즈 에이피에스 식품, 에너지 및/또는 지방 섭취 감소를 위한 비피더스균
WO2017178315A1 (en) * 2016-04-14 2017-10-19 Dupont Nutrition Biosciences Aps Bifidobacteria for increasing lean body mass
JP6986856B2 (ja) * 2016-05-10 2021-12-22 協同乳業株式会社 トリメチルアミンを産生し難い腸内菌叢を形成するためのプロバイオティクス組成物および方法
EP3272396A1 (en) * 2016-07-18 2018-01-24 Bionou Research, S.L. Use of probiotics in the treatment and/or prevention of atopic dermatitis
CN106619742A (zh) * 2016-11-08 2017-05-10 江西益盟科技有限公司 治疗糖尿病的乳酸菌组合物及其制备方法
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
CA3052134C (en) * 2017-01-31 2023-01-03 University-Industry Cooperation Group Of Kyung Hee University Novel lactic acid bacteria and use thereof
MY197201A (en) * 2017-02-10 2023-05-31 Perfect China Co Ltd Novel probiotics bifidobacteria strains
CN106617096B (zh) * 2017-02-15 2020-12-18 中国农业大学 一种增强胰岛功能的双歧杆菌及其应用
CN107050065B (zh) * 2017-03-31 2021-03-30 杭州远大生物制药有限公司 双歧四联活菌组合物的新应用
CN107410486A (zh) * 2017-06-27 2017-12-01 合肥工业大学 一种降血糖玫瑰茄发酵乳的制备方法
EP3645025B1 (en) * 2017-06-30 2022-09-14 N.V. Nutricia Synbiotic composition for preventing atherosclerosis
EP3662087B1 (en) * 2017-08-06 2022-10-05 Second Genome, Inc. Streptococcus australis as a biotherapeutics
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
CN107723257A (zh) * 2017-09-20 2018-02-23 深圳市晨光乳业有限公司 一种动物双歧杆菌及其食品组合物
EP3688196A4 (en) * 2017-09-26 2021-07-14 Second Genome, Inc. GEMELLA SANGUINIS AS BIOTHERAPEUTICS
US20200261516A1 (en) * 2017-10-31 2020-08-20 Morinaga Milk Industry Co., Ltd. Composition for Increasing Muscle Mass
WO2019084617A1 (en) * 2017-11-01 2019-05-09 Medlab Ip Pty Ltd Modulation of intestinal microbiota in pre-diabetes and type 2 diabetes
US20210177031A1 (en) * 2017-11-09 2021-06-17 Societe Des Produits Nestle S.A. An array of age-tailored nutritional formula for infants and young children for use in the prevention of sub-optimal body composition
EP3777868A4 (en) * 2018-03-23 2021-12-01 Morinaga Milk Industry Co., Ltd. YOUNG CHILDREN'S COMPOSITION FOR THE PREVENTION OF HIGH BLOOD PRESSURE DISORDERS IN CHILDHOOD AND BEYOND
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
CN109259243A (zh) * 2018-09-26 2019-01-25 广州普维君健药业有限公司 降三高的组合物及其制备方法和应用
WO2020113579A1 (zh) * 2018-12-07 2020-06-11 深圳华大生命科学研究院 单形巨单胞菌在预防和/或治疗代谢性疾病中的用途
CN109486715B (zh) * 2018-12-07 2022-07-15 江苏靶标生物医药研究所有限公司 一种富硒长双歧杆菌及其制备方法和应用
CN109998113A (zh) * 2019-04-18 2019-07-12 广东省微生物研究所（广东省微生物分析检测中心） 一种具有降血糖功效的益生菌制剂的功能性食品
CN110150669B (zh) * 2019-04-29 2022-09-06 河北一然生物科技股份有限公司 一种适于糖尿病患者食用的益生菌组合物及其应用
WO2020240033A1 (en) * 2019-05-30 2020-12-03 University College Cork - National University Of Ireland, Cork Gaba-producing culturable bacteria and use for improving health
CN110604749B (zh) * 2019-08-30 2020-08-14 北京农学院 动物双歧杆菌a12及其在控制糖尿病或高血脂症特别是体重增加或肥胖中的应用
WO2021062250A1 (en) 2019-09-25 2021-04-01 Tall Goods, Llc Methods for producing probiotics fortified avian eggs and egg products and formulations thereof
CN113197313B (zh) * 2020-09-02 2023-10-27 内蒙古蒙牛乳业（集团）股份有限公司 具有改善胰岛素抵抗及空腹血糖的益生菌组合物及制备方法
CA3188423A1 (en) 2020-09-04 2022-03-10 Francois-Pierre Martin Compositions and methods for providing health benefits in an animal
CN113207961B (zh) * 2020-09-29 2023-06-23 内蒙古蒙牛乳业（集团）股份有限公司 乳双歧杆菌MN-Gup乳制品及其在改善2型糖尿病中应用
CN112535275A (zh) * 2020-12-10 2021-03-23 淮北师范大学 一种具有α-葡萄糖苷酶抑制活性的发酵菊花凉拌酱的制备方法
CN113215030B (zh) * 2021-04-12 2022-10-25 天津中医药大学 约氏乳杆菌eu03及其用途
CN113249264B (zh) * 2021-06-03 2021-11-23 北京量化健康科技有限公司 一株青春双歧杆菌及其在代谢综合征中的应用
CN113678979A (zh) * 2021-08-25 2021-11-23 上海英库商务咨询有限公司 用于促使ii型糖尿病人群胰岛素合成和分泌的固体饮料
CN113995720B (zh) * 2021-11-15 2023-03-17 郑州大学 一种乳剂包被型益生菌制剂及其制备方法与应用
CN115466689B (zh) * 2022-02-09 2023-06-16 中国科学技术大学 用于预防和/或治疗代谢类疾病的益生菌组合物及其应用
CN115281345A (zh) * 2022-04-06 2022-11-04 金华银河生物科技有限公司 一种复合益生菌组合物联合二甲基胍治疗ⅱ型糖尿病的用途
WO2023219460A1 (ko) * 2022-05-12 2023-11-16 주식회사 지아이바이옴 락토바실러스 퍼멘텀 균주 및 대사조절제를 포함하는 병용 요법을 이용한 대사질환 예방 또는 치료용 조성물
CN115948273B (zh) * 2022-06-21 2023-07-18 合肥瀚微生物科技有限公司 治疗糖尿病及相关病症的两歧双歧杆菌
CN115137757A (zh) * 2022-07-29 2022-10-04 承葛健康科技(广东)有限公司 一种辅助降血糖的益生菌组合物
CN115607576A (zh) * 2022-09-29 2023-01-17 青岛东海药业有限公司 一种用于防治糖尿病及白色念珠菌感染并发症的组合物及其应用
CN116891810A (zh) * 2022-12-15 2023-10-17 杭州娃哈哈科技有限公司 具有降血糖功效的益生菌组合物、益生菌益生元复合制剂
WO2024134035A1 (fr) * 2022-12-22 2024-06-27 Sorbonne Universite Composition et utilisation de turicimonas muris pour le traitement de maladies métaboliques
CN117487692B (zh) * 2023-10-08 2025-04-15 卡士酸奶(苏州)有限公司 一株缓解糖尿病症状的格氏乳杆菌及其应用
CN117187145B (zh) * 2023-10-20 2024-07-16 深圳保时健生物工程有限公司 一株具有降脂、降血糖和减重功能的嗜酸乳杆菌goldgut-la100及其应用
CN117838737A (zh) * 2023-12-21 2024-04-09 汤臣倍健股份有限公司 一种短双歧杆菌207-1及其在调节脂代谢方向的应用
TW202602475A (zh) * 2024-04-16 2026-01-16 香港商香港微生物菌群創新中心有限公司 組合物、其用途和預防或治療肝相關疾病或病症的方法
CN119286727B (zh) * 2024-11-28 2025-02-28 山东环亿生物科技有限公司 一种动物双歧杆菌动物乳亚种9360-2及其在预防和/或治疗心脑血管疾病中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002003A (en) 1930-09-20 1935-05-21 Ig Farbenindustrie Ag Production of acetylene and carbon black
JP2779963B2 (ja) * 1989-02-09 1998-07-23 株式会社林原生物化学研究所 ビフィズス菌増殖促進剤
SE510753C2 (sv) * 1997-08-05 1999-06-21 Probi Ab Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
SE0004124D0 (sv) 2000-11-10 2000-11-10 Probi Ab New use
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms
KR100527103B1 (ko) * 2003-02-04 2005-11-09 최현우 지질대사개선효능을 갖는 미생물을 함유한 성인병 예방 및치료용 조성물 및 이의 용도
EP2351492B1 (en) * 2005-02-28 2014-08-20 N.V. Nutricia Nutritional composition with probiotics
SE529185C2 (sv) 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
WO2007084059A1 (en) * 2006-01-20 2007-07-26 Bjoerk Inger A food composition comprising amino acids
US8309076B2 (en) 2006-08-04 2012-11-13 Bioneer Corporation Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
CN101310606A (zh) * 2007-05-24 2008-11-26 大连森佰澳科技有限公司 含有双歧杆菌功能信号分子和益生元的液体奶制品
EP2011506A1 (en) 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
EP2022502A1 (en) 2007-08-10 2009-02-11 Nestec S.A. Lactobacillus rhamnosus and weight control
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria

Also Published As

Publication number Publication date
EP3181134A1 (en) 2017-06-21
WO2010146568A3 (en) 2011-05-05
CN102458415B (zh) 2015-05-20
EP2808024A1 (en) 2014-12-03
US20250041358A1 (en) 2025-02-06
CN104784220A (zh) 2015-07-22
CN102458415A (zh) 2012-05-16
PL2442814T3 (pl) 2019-04-30
CN104784694A (zh) 2015-07-22
PL2808024T3 (pl) 2019-09-30
PL3181134T3 (pl) 2020-04-30
EP2442814B1 (en) 2018-09-26
US20190307815A1 (en) 2019-10-10
US20180021391A1 (en) 2018-01-25
BRPI1014081A2 (pt) 2016-04-19
ES2729765T3 (es) 2019-11-06
EP2808024B1 (en) 2019-04-24
WO2010146568A2 (en) 2010-12-23
ES2702977T3 (es) 2019-03-06
CN104770739A (zh) 2015-07-15
EP2442814A2 (en) 2012-04-25
DK2808024T3 (da) 2019-06-11
US20210322491A1 (en) 2021-10-21
US20120107291A1 (en) 2012-05-03
EP3181134B1 (en) 2019-10-30
US20140348796A1 (en) 2014-11-27
US20230248786A1 (en) 2023-08-10
US20200316144A1 (en) 2020-10-08
US12594309B2 (en) 2026-04-07
CN104784219A (zh) 2015-07-22
ES2763137T3 (es) 2020-05-27
DK3181134T3 (da) 2020-01-20

Similar Documents

Publication Publication Date Title
US12594309B2 (en) Bifidobacteria for treating diabetes and related conditions
US20240335485A1 (en) Bifidobacteria for treating cardiac conditions
US10543239B2 (en) Lactic acid bacteria and bifidobacteria for treating endotoxemia
US20110189149A1 (en) New Uses of Lactic Acid Bacteria and Bifidobacteria
US20250262255A1 (en) Lactobacilli for treating cardiac dysfunction
BRPI1014081B1 (pt) Uso de uma bactéria bifidobacterium animalis subsp. lactis cepa 420 para tratar doenças em um mamífero